Voya Investment Management LLC Sells 29,051 Shares of Phreesia, Inc. $PHR

Key Points

• Voya Investment Management LLC has reduced its stake in Phreesia, Inc. by 18.2% in the first quarter, now owning about 0.22% of the company, valued at approximately $3.3 million.
• Phreesia reported a quarterly earnings per share of $0.01, which beat analysts' expectations, alongside a revenue increase of 14.9% compared to the previous year.
• Multiple analysts have increased their price targets for Phreesia, with Canaccord Genuity recently setting a target of $38.00 and the stock receiving a Buy consensus rating.

Voya Investment Management LLC lessened its holdings in Phreesia, Inc. (NYSE:PHR - Free Report) by 18.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 130,223 shares of the company's stock after selling 29,051 shares during the period. Voya Investment Management LLC owned approximately 0.22% of Phreesia worth $3,328,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. KBC Group NV acquired a new stake in shares of Phreesia in the 1st quarter valued at $74,000. CWM LLC increased its position in Phreesia by 994.9% during the first quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after buying an additional 3,671 shares during the period. Smartleaf Asset Management LLC increased its position in Phreesia by 53.0% during the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock worth $137,000 after buying an additional 1,825 shares during the period. GAMMA Investing LLC boosted its stake in Phreesia by 10,605.7% during the 1st quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock worth $145,000 after purchasing an additional 5,621 shares during the period. Finally, BNP Paribas Financial Markets acquired a new position in Phreesia in the 4th quarter valued at about $163,000. Hedge funds and other institutional investors own 92.10% of the company's stock.

Insider Buying and Selling at Phreesia

In other news, Director Mark Douglas Smith sold 7,000 shares of Phreesia stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $29.00, for a total transaction of $203,000.00. Following the sale, the director owned 37,353 shares of the company's stock, valued at approximately $1,083,237. This trade represents a 15.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Allison C. Hoffman sold 3,133 shares of the firm's stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $72,936.24. Following the completion of the transaction, the general counsel directly owned 139,037 shares of the company's stock, valued at approximately $3,236,781.36. This trade represents a 2.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 128,343 shares of company stock valued at $3,739,343 in the last three months. Company insiders own 5.50% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on PHR. Stephens reissued an "overweight" rating and issued a $32.00 price target on shares of Phreesia in a report on Wednesday, September 3rd. Mizuho initiated coverage on shares of Phreesia in a research note on Wednesday, August 27th. They set an "outperform" rating and a $36.00 price target on the stock. Canaccord Genuity Group upped their price target on shares of Phreesia from $34.00 to $38.00 and gave the company a "buy" rating in a report on Friday, September 5th. Raymond James Financial set a $33.00 price target on Phreesia and gave the stock an "outperform" rating in a research report on Friday, September 5th. Finally, Truist Financial increased their price objective on shares of Phreesia from $35.00 to $36.00 and gave the company a "buy" rating in a report on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $34.08.

Phreesia Stock Down 0.7%

Shares of Phreesia stock traded down $0.18 during midday trading on Tuesday, reaching $24.56. 173,438 shares of the company's stock traded hands, compared to its average volume of 602,198. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -58.52 and a beta of 0.72. The company's 50 day simple moving average is $27.51 and its 200 day simple moving average is $26.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $32.76.

Phreesia (NYSE:PHR - Get Free Report) last posted its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.08. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The firm had revenue of $117.26 million during the quarter, compared to analyst estimates of $116.39 million. During the same period in the previous year, the company earned ($0.03) EPS. The company's revenue for the quarter was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. Equities analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.